Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
Séverine Vermeire(KU Leuven), Walter Reinisch(Medical University of Vienna), Maria Kłopocka(Nicolaus Copernicus University), Bruce Salzberg(Atlanta Gastroenterology Associates), Dino Tarabar(Military Medical Academy), Robert Clare(Pfizer (United States)), William J. Sandborn(University of San Diego), Tomáš Vaňásek, Fabio Cataldi(Pfizer (United States)), Silvio Danese(IRCCS Ospedale San Raffaele), Alaa Ahmad(All India Institute of Medical Sciences), Xavier Hébuterne(Université Côte d'Azur), Paul Hellstern(Clinical Research Atlanta), Mina Hassan‐Zahraee(Pfizer (United States)), Miles Sparrow(Alfred Health), Joo Sung Kim(National University College), Vivek Pradhan(Pfizer (United States)), Michelle Hinz(Pfizer (United States)), Miloš Greguš, Kenneth J. Gorelick
Cited by 198
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
|New England Journal of Medicine|2006|1k